Health

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced thatthe International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facili...

2023-05-22 16:30 2440

Xinhua Silk Road: Conference held to foster digital, AI-driven life and health industry development in Wuxi, E. China

BEIJING, May 22, 2023 /PRNewswire/ -- The 2023 Taihu Bay Future Healthcare Conference (2023 TBHC) was held on Thursday in Wuxi City in eastChina's Jiangsu Province to better integrate with digitalization and artificial intelligence (AI) to enable local life and health industry development.

2023-05-22 16:06 1774

Laekna announces first IND clearance by U.S. FDA for internally-discovered LAE102

SHANGHAI and WARREN, N.J. , May 21, 2023 /PRNewswire/ -- Laekna, a clinical-stage biotechnology company dedicated to bringing novel therapies to cancer and liver fibrosis patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug ...

2023-05-21 22:23 2229

EUDA Health Holdings Limited Announces Receipt of Nasdaq Listing Delinquency Letter

SINGAPORE, May 19, 2023 /PRNewswire/ -- EUDA Health Holdings Limited (the "Company" or "EUDA") (NASDAQ: EUDA, EUDAW), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, announced today that it received a delinquency notifica...

2023-05-20 04:05 5628

Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans...

2023-05-20 00:55 5051

Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial

* Positive primary endpoint result of objective response rate (ORR) from the planned interim analysis of Phase II trial in advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJ). * Top-line data of the final analysis from Phase II to be announced in the second half of next year. S...

2023-05-19 21:00 2324

Health In Tech Partners with Health Direct Partners to provide self-funded employer groups with full plan transparency, savings, and improved employee health.

The revolutionary collaboration brings a robust medical management system to groups nationwide. STUART, Fla., May 19, 2023 /PRNewswire/ -- Health In Tech, an industry-leading insurtech company that delivers disruptive innovation and reimagines self-funded health plans, is thrilled to announce it...

2023-05-19 20:30 2278

2023 Qingdao∙ Global Venture Capital Conference Comes to a Close

QINGDAO, China, May 19, 2023 /PRNewswire/ -- On the afternoon of May 13, 2023, theQingdao∙ Global Venture Capital Conference officially ended. Over the past two days, more than 1,000 leading investors, economists, entrepreneurs and representatives from financial institutions in the field of ventu...

2023-05-19 20:00 2237

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

-  New investigational data evaluating Fexuprazan in a Korean clinical trial program for healing erosive esophagitis (EE) regardless of food intake, and in a Chinese pivotal clinical trial program for the treatment of EE SEOUL, South Korea and CHICAGO, May 19, 2023 /PRNewswire/ -- Daewoong Pharm...

2023-05-19 20:00 2184

The 133rd Canton Fair Gathers Top Medical Equipment to Unlock the Health Code

GUANGZHOU, China, May 19, 2023 /PRNewswire/ -- Global healthcare takes center stage as the world recovers from the COVID-19 pandemic. As the public becomes more vigilant about their health, medical institutions are also stepping up their game in providing top-notch services and equipment. In the ...

2023-05-19 19:49 2200

HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease

* Tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score (CCSS) or in improvement in Eye Dryness Score (EDS) assessed at week 8 in subjects with dry eye disease (DED), compared to vehicle. * However,...

2023-05-19 19:00 2014

ExoCoBio obtained a US Patent for Rose Stem Cell-derived Exosome (RSCE™)

-  The first plant stem cell-derived exosome patent in the US -  The 5th patent allowance following 3 in Korea and 1 in Japan -  An important milestone for the global plant stem cell-derived exosome industry SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- ExoCoBio, one of the top three exosome...

2023-05-19 16:34 3674

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targetin...

2023-05-18 21:30 2344

Neurophet receives FDA 510(k) Clearance for Neurophet AQUA

- Flagship products Neurophet AQUA and Neurophet SCALE PET both received 510k - Plans to cooperate with radiology AI solution platform companies to enter the U.S. market SEOUL, South Korea, May 18, 2023 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease...

2023-05-18 21:00 2096

CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.

SHANGHAI, May 18, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CARsgen has initiated patient enrollment for Phase 2 of the clinic...

2023-05-18 20:50 2282

Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer

SHANGHAI, May 18, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu C...

2023-05-18 16:00 2060

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

-  ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncologyand Antengene's third drug candidate to enter clinical studies in the U.S. -  The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacolog...

2023-05-18 02:47 2695

United Imaging Unveils a Full Portfolio of Products at CMEF 2023, Highlighting Its AI Capabilities across Modalities

SHANGHAI, May 17, 2023 /PRNewswire/ -- United Imaging unveiled its full range of products, including PET/CT, PET/MR, MR, CT, DR, RT, and digital solutions, at the China International Medical Equipment Fair (CMEF) recently, highlighting the products' AI capacity across modalities.

2023-05-17 20:00 3078

Skyline Therapeutics Brings Multiple Data Presentations to ASGCT 2023

SHANGHAI, May 17, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, is showcasing multiple data presentations at the American Society of Gene and Cell Therapy ...

2023-05-17 18:00 2033

Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022

NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and entering into the operation of a ...

2023-05-17 05:00 3162
1 ... 85868788899091 ... 273